Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Kadmon Holdings Inc (KDMN) USD0.001

Sell:$4.46 Buy:$4.47 Change: $0.01 (0.22%)
Market closed |  Prices as at close on 24 January 2020 | Switch to live prices |
Sell:$4.46
Buy:$4.47
Change: $0.01 (0.22%)
Market closed |  Prices as at close on 24 January 2020 | Switch to live prices |
Sell:$4.46
Buy:$4.47
Change: $0.01 (0.22%)
Market closed |  Prices as at close on 24 January 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company's other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company's portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson's disease.

Contact details

Address:
450 E 29th St
NEW YORK
10016-8367
United States
Telephone:
+1 (212) 3086000
Website:
kadmon.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
KDMN
ISIN:
US48283N1063
Market cap:
$713.12 million
Shares in issue:
159.53 million
Sector:
Biotechnology
Exchange:
New York Stock Exchange
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Tasos Konidaris
    Interim Chairman of the Board
  • Harlan Waksal
    President, Chief Executive Officer, Director
  • Steven Meehan
    Chief Financial Officer, Executive Vice President
  • Gregory Moss
    Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
  • John Ryan
    Executive Vice President, Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.